| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 12/03/2025 | 21:02 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 12/03/2025 | 21:01 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 12/03/2025 | 03:20 | GlobeNewswire Inc. | Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 10/03/2025 | 21:01 | GlobeNewswire Inc. | Mineralys Therapeutics Announces Proposed Public Offering of Common Stock | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 10/03/2025 | 12:00 | GlobeNewswire Inc. | Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 07/03/2025 | 22:01 | GlobeNewswire Inc. | Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 25/02/2025 | 00:59 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 14/02/2025 | 12:03 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 12/02/2025 | 13:00 | GlobeNewswire Inc. | Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 05/02/2025 | 22:05 | GlobeNewswire Inc. | Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025 | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 04/02/2025 | 14:00 | GlobeNewswire Inc. | Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 08/01/2025 | 14:00 | GlobeNewswire Inc. | Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 13/11/2024 | 22:27 | Edgar (US Regulatory) | Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 12/11/2024 | 14:36 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 11/11/2024 | 22:05 | GlobeNewswire Inc. | Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 05/11/2024 | 22:05 | GlobeNewswire Inc. | Mineralys Therapeutics to Participate in Upcoming Investor Conferences | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 30/10/2024 | 13:00 | GlobeNewswire Inc. | Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 22/10/2024 | 14:00 | GlobeNewswire Inc. | Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 25/09/2024 | 14:00 | GlobeNewswire Inc. | Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 13/08/2024 | 22:05 | GlobeNewswire Inc. | Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 05/08/2024 | 22:05 | GlobeNewswire Inc. | Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024 | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 17/06/2024 | 22:31 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 14/06/2024 | 14:00 | GlobeNewswire Inc. | Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 09/05/2024 | 13:00 | GlobeNewswire Inc. | Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 06/05/2024 | 14:00 | GlobeNewswire Inc. | Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 02/05/2024 | 14:00 | GlobeNewswire Inc. | Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024 | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 21/03/2024 | 12:00 | GlobeNewswire Inc. | Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 13/03/2024 | 21:05 | GlobeNewswire Inc. | Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024 | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 15/02/2024 | 22:20 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:MLYS | Mineralys Therapeutics Inc |
| 08/02/2024 | 14:00 | GlobeNewswire Inc. | Mineralys Therapeutics Announces $120 Million Private Placement Financing | NASDAQ:MLYS | Mineralys Therapeutics Inc |
